The combination of IDO1 shRNA and the Her2/neu DNA vaccine has induced a better anti-tumor effect than the Her2/neu DNA vaccine alone, in an endogenous Her2/neu-overexpressing bladder tumor model [76]. This evidence concerns the gene ERBB2 and neoplasm.